ClinicalTrials.gg
TerminatedNCT00992732Updated Aug 1, 2011

Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

A Phase 2 interventional study of HQK-1004 and Valganciclovir (may substitute with ganciclovir) in Lymphoid Malignancies and Lymphoproliferative Disorders, sponsored by HemaQuest Pharmaceuticals Inc.. Terminated at 8 sites in United States. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2011-08-01.

Sponsored by HemaQuest Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies in Lymphoproliferative Disorders with a site in United States — 28 open to participants now, 46 under way, 2 of them phase 3. Lymphoproliferative Disorders · United States.

Enrollment
120th of 127
1 · median 37
Started
2010
with 3 others
Phase 2
48 of 147
9 open now
Registered
67th of 147
by date

Among the 147 studies in Lymphoproliferative Disorders with a site in United States, this one is the 120th largest by enrollment of the 127 interventional ones that give a count, is one of 4 that started in 2010, is one of 48 in phase 2, and was the 67th registered.

Lymphoproliferative Disorders

216 studies on the registry are indexed under Lymphoproliferative Disorders; 49 are open to participants now.

Browse Lymphoproliferative Disorders studies →

Open to participants now

28 of the 147 studies in Lymphoproliferative Disorders with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Lymphoproliferative Disorders studies recruiting now, 28 (72%) set no upper age limit and 6 (15%) stop at 75 or younger; 18 take children under 18; 2 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Lymphoproliferative Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if treatment with HQK-1004 and valganciclovir will result in complete or partial responses in patients with EBV-positive lymphoid malignancies or lymphoproliferative disorders.

03

Conditions studied

  • Lymphoid Malignancies
  • Lymphoproliferative Disorders
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed lymphoid or lymphoproliferative disorder with EBV detected by either immunohistochemistry or in situ hybridization. Pathology can be assessed on either a current or previous . All disease stages are eligible
  • Disease that is or relapsed after at least one prior standard therapeutic regimen, which includes biologic agents (e.g., monoclonal antibodies), chemotherapy or chemoradiotherapy regimens. Prior therapy may include high dose chemotherapy and stem cell rescue or bone marrow transplantation
  • Bidimensionally by computerized tomography (CT) or magnetic resonance imaging (MRI; patients with sensitivity to contrast or for tumor types that are less accurately measured by CT) scan or physical measurement (cutaneous lesions only) with at least 1 lesion ≥ 10 mm in the greatest diameter. PET-CT should be used at baseline for patients with Hodgkin's Disease (HD) or diffuse large B-cell lymphoma (DLBCL).
  • ≥ 500/mm3 and count ≥ 50,000/mm3
  • ≤ 2.0 times (ULN) with the exception of patients with Gilbert's syndrome (bilirubin ≤ 3.5 times ULN allowed), and both and ALT ≤ 3 times ULN
  • Serum creatinine ≤ 2.0 mg/dL

Exclusion criteria

Exclusion Criteria:

  • Patients who have not recovered from previous treatment with chemotherapy
  • Patients who have been treated with biologic agents within two weeks prior to first dose of HQK-1004
  • Uncontrolled ischemic heart disease or uncontrolled congestive heart failure, or myocardial infarction within the past 3 months
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    HQK-1004 + Valganciclovir

    Drug: HQK-1004 · Drug: Valganciclovir (may substitute with ganciclovir)

Interventions

  • DrugArginine butyrateStudies of Arginine butyrateArginine butyrate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)

    Also known as: arginine butyrate

  • DrugValganciclovir (may substitute with ganciclovir)

    Drug page: ValganciclovirStudies of ValganciclovirValganciclovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.

06

What researchers measure

Primary outcomes

  1. Overall response rate

    Time frame: Days 21, 42, 84 and 126

Secondary outcomes

  1. Safety and tolerability as measured by adverse events, physical exams, ECG, and laboratory evaluations

    Time frame: through end of treatment (up to Day 126) and 30 days post last dose

  2. Overall and progression-free survival

    Time frame: through end of treatment (up to Day 126), then every 8 weeks for 1 year post last dose

07

Study locations

8 sites
  • LPCH/Stanford
    Palo Alto, California 94304, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Washington University School of Medicine
    St. Louis, Missouri 63110, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Abramson Cancer Center of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Feigin Center - Center for Cell and Gene Therapy
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010 and a primary completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2009
First posted
Oct 9, 2009
Start
May 2010
Primary completionActual
Nov 2010
Results delay requested
Jul 28, 2011
Last update
Aug 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00992732
Lead sponsor
HemaQuest Pharmaceuticals Inc.
First posted
Oct 9, 2009
Start date
May 2010
Primary completion
Nov 2010
Last update
Aug 1, 2011

Study contacts

Ron Berenson, MD
study director · HemaQuest Pharmaceuticals Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arginine butyrate

Start the discussion